Gaithersburg, Md – Jan 17 2024
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW), a technology-enabled drug development company utilizing AI and machine learning to drive pharmaceutical advancements, today announced promising early results from its collaboration with the Lieber Institute for Brain Development (LIBD). This global strategic partnership has successfully stratified brain expression data, offering potentially unprecedented insights into psychiatric conditions and paving the way for more targeted treatments.
Revolutionizing Psychiatric Research with AI
Utilizing BullFrog AI’s proprietary bfLEAP™ artificial intelligence platform, researchers have analyzed gene expression data from over 2,800 brain samples. This dataset spans schizophrenia, bipolar disorder, major depressive disorder, and non-psychiatric control brains. For the first time, subjects were clustered solely on their biological data, independent of their behavioral diagnoses.
“This collaboration marks a pivotal moment in psychiatric research,” said Vin Singh, CEO of BullFrog AI. “By employing our bfLEAP™ platform on LIBD’s unrivaled brain data, we have gained invaluable insights into the biological underpinnings of psychiatric disorders. These preliminary findings could transform treatment strategies and open the door to revenue-generating partnerships with pharmaceutical companies.”
Unlocking Biological Subtypes for Personalized Medicine
Graph analytics applied to the data have revealed distinct differences and similarities in biological pathways across psychiatric disorders. This approach has identified biological subtypes within individual conditions, a critical step toward the development of precision medicine in mental health.
Daniel R. Weinberger, M.D., Director and CEO of LIBD, stated, “Our collaboration with BullFrog AI has enabled us to apply cutting-edge AI technologies to our extensive brain data. The preliminary results offer novel insights at the gene level that may only be discoverable through AI-driven methodologies, providing a new perspective on diagnosing and treating psychiatric disorders.”
A Vast Market Opportunity for Mental Health Solutions
The global need for effective psychiatric treatments is greater than ever, with rising demand for mental health solutions. By identifying biological subtypes within disorders, BullFrog AI and LIBD are advancing scientific understanding and creating pathways to innovative therapeutic solutions tailored to individual patient profiles.
The agreement between BullFrog AI and LIBD, originally announced in September 2023, grants BullFrog AI exclusive access to LIBD’s brain data with the potential to commercialize products or services derived from the collaboration. This partnership merges AI-driven analytics with world-class neuropsychiatric research, setting a new standard in the development of novel treatments for brain disorders.
About BullFrog AI
BullFrog AI is at the forefront of AI-driven drug development, integrating advanced machine learning to enhance the success of pharmaceuticals and biologics. Through strategic collaborations with research institutions, including George Washington University, the company is pioneering new approaches to tackling complex diseases. BullFrog AI’s proprietary bfLEAP™ platform is being utilized to advance BF-114 for the treatment of obesity-related liver diseases. More about news
About the Lieber Institute for Brain Development (LIBD)
The Lieber Institute for Brain Development is dedicated to translating genetic and molecular discoveries into clinical advancements that transform the lives of individuals affected by schizophrenia and other brain disorders. As an independent, not-for-profit medical research institute, LIBD houses the world’s largest postmortem brain repository for the study of neuropsychiatric conditions.
By